Dentsply Sirona's Q3 Losses Narrow Amidst Sales Decline, Impairments

Ticker: XRAY · Form: 10-Q · Filed: 2025-11-06T00:00:00.000Z

Sentiment: bearish

Topics: Dental Equipment, Medical Devices, Net Loss, Revenue Decline, Goodwill Impairment, North America Sales, European Growth

Related Tickers: XRAY, ALGN, HSIC, ZTS

TL;DR

**XRAY's Q3 shows narrowing losses but sales are still sinking, especially in the US, making it a risky bet despite the slight improvement in net loss.**

AI Summary

DENTSPLY SIRONA Inc. (XRAY) reported a significant net loss of $427 million for the three months ended September 30, 2025, compared to a net loss of $494 million in the prior year, representing a 13.56% improvement. For the nine months, the net loss was $452 million, an improvement from $480 million in 2024. Total net sales decreased by 5% to $904 million in Q3 2025 from $951 million in Q3 2024, and by 5.88% to $2,719 million for the nine months from $2,888 million. The company incurred substantial goodwill and intangible asset impairments of $262 million in Q3 2025 and $497 million for the nine months. Geographically, U.S. net sales declined significantly by 22.2% to $291 million in Q3 2025, while European sales increased by 10.09% to $382 million. The company's cash and cash equivalents increased to $363 million as of September 30, 2025, from $272 million at December 31, 2024, despite a decrease in net cash provided by operating activities from $374 million in 2024 to $134 million in 2025 for the nine-month period.

Why It Matters

DENTSPLY SIRONA's continued net losses and declining sales, particularly a 22.2% drop in the crucial U.S. market, signal persistent operational challenges and competitive pressures in the dental equipment and consumables sector. The substantial goodwill and intangible asset impairments, totaling $497 million year-to-date, indicate a reevaluation of asset values and potentially weaker future earnings prospects, which could erode investor confidence. For employees, these financial struggles might lead to restructuring or cost-cutting measures. Customers could see impacts on product development or support, while the broader market might view this as a sign of a challenging environment for dental device manufacturers, potentially affecting competitors like Align Technology or Henry Schein.

Risk Assessment

Risk Level: high — The company reported a net loss of $427 million in Q3 2025 and $452 million for the nine months, indicating ongoing unprofitability. Furthermore, significant goodwill and intangible asset impairments of $262 million in Q3 2025 and $497 million for the nine months highlight potential overvaluation of past acquisitions and future earnings uncertainty.

Analyst Insight

Investors should exercise extreme caution and consider divesting or avoiding XRAY shares due to persistent net losses, declining sales, and substantial asset impairments. Monitor future filings for any signs of sustained revenue growth, particularly in the U.S. market, and a reduction in impairment charges before considering a long position.

Financial Highlights

revenue
$904M
total Assets
$5,653M
net Income
$-427M
eps
$-2.14
gross Margin
48.8%
cash Position
$363M
revenue Growth
-5.0%

Revenue Breakdown

SegmentRevenueGrowth
U.S.$291M-22.2%
Europe$382M+10.09%

Key Numbers

Key Players & Entities

FAQ

What were DENTSPLY SIRONA's net sales for the third quarter of 2025?

DENTSPLY SIRONA reported net sales of $904 million for the three months ended September 30, 2025. This represents a decrease from $951 million in the same period of 2024.

How did DENTSPLY SIRONA's net loss change in Q3 2025 compared to Q3 2024?

The net loss attributable to DENTSPLY SIRONA improved to $427 million in Q3 2025, compared to a net loss of $494 million in Q3 2024. This is a 13.56% reduction in net loss.

What was the impact of goodwill and intangible asset impairments on DENTSPLY SIRONA's Q3 2025 results?

DENTSPLY SIRONA recorded significant goodwill and intangible asset impairments of $262 million in Q3 2025. For the nine months ended September 30, 2025, these impairments totaled $497 million.

Which geographic region saw the largest sales decline for DENTSPLY SIRONA in Q3 2025?

The United States experienced the largest sales decline, with net sales falling 22.2% to $291 million in Q3 2025 from $374 million in Q3 2024.

Did DENTSPLY SIRONA's European sales grow in Q3 2025?

Yes, DENTSPLY SIRONA's European net sales increased by 10.09% to $382 million in Q3 2025, up from $347 million in Q3 2024.

What was DENTSPLY SIRONA's cash and cash equivalents balance at September 30, 2025?

As of September 30, 2025, DENTSPLY SIRONA had cash and cash equivalents of $363 million, an increase from $272 million at December 31, 2024.

How did DENTSPLY SIRONA's operating cash flow change for the first nine months of 2025?

Net cash provided by operating activities for the nine months ended September 30, 2025, was $134 million, a significant decrease from $374 million in the same period of 2024.

What is DENTSPLY SIRONA's current outstanding common stock as of October 17, 2025?

As of October 17, 2025, DENTSPLY SIRONA Inc. had 199,551,969 shares of common stock outstanding.

What are the key accounting pronouncements DENTSPLY SIRONA is evaluating for future impact?

DENTSPLY SIRONA is evaluating ASU No. 2024-03 and ASU No. 2025-01 regarding disaggregation of income statement expenses, ASU No. 2025-06 on internal-use software costs, and ASU No. 2025-07 on derivatives and revenue from customer contracts.

Does DENTSPLY SIRONA's business experience seasonality?

Yes, DENTSPLY SIRONA's business is subject to quarterly fluctuations, with sales generally stronger in the second and fourth quarters and weaker in the first and third quarters due to factors like dental tradeshows, patient traffic, and holiday timing.

Risk Factors

Industry Context

The dental technology and consumables market is highly competitive, driven by innovation in areas like digital dentistry, implants, and orthodontics. Companies face pressure to invest in R&D while managing global supply chains and varying regional economic conditions. Consolidation remains a trend, with companies seeking scale and synergistic benefits.

Regulatory Implications

The company must navigate complex global regulations related to medical devices, including product approvals, manufacturing standards, and data privacy. Changes in healthcare policies or reimbursement rates in key markets like the U.S. can significantly impact demand and profitability.

What Investors Should Do

  1. Monitor the sustainability of European sales growth and investigate the drivers behind the significant U.S. sales decline to assess market share shifts and competitive positioning.
  2. Analyze the reasons for the substantial goodwill and intangible asset impairments to understand the underlying issues with past acquisitions and their impact on future performance.
  3. Scrutinize the significant drop in operating cash flow and the large provision for income taxes despite net losses to assess the company's true cash generation ability and potential tax liabilities.
  4. Evaluate management's strategy to reverse the revenue decline and improve operational efficiency, particularly in the U.S. market, and assess the timeline for potential recovery.

Glossary

Goodwill and intangible asset impairments
A non-cash accounting charge recognized when the carrying value of goodwill or other intangible assets on the balance sheet is deemed to be higher than their recoverable amount, indicating a permanent reduction in value. (The company recorded significant impairments totaling $262 million in Q3 2025, directly impacting reported net loss and reflecting a decline in the value of acquired businesses or assets.)
Net sales
The total revenue generated from the sale of goods and services after deducting returns, allowances, and discounts. (Total net sales decreased by 5% to $904 million in Q3 2025, indicating a contraction in the company's top-line performance.)
Operating loss
The loss incurred from a company's normal business operations before accounting for interest and taxes. (The company reported an operating loss of $218 million in Q3 2025, highlighting significant losses from core business activities, exacerbated by impairments.)
Provision for income taxes
An accounting estimate of the amount of income tax expense that a company expects to pay for a given period. (A substantial provision of $198 million was recorded in Q3 2025, despite a net loss, which warrants further investigation into tax liabilities or deferred tax asset valuation.)
Net cash provided by operating activities
The net amount of cash generated from a company's normal business operations over a period. (This metric significantly decreased to $134 million for the nine months ended September 30, 2025, from $374 million in the prior year, indicating a weakening cash generation capability from operations.)

Year-Over-Year Comparison

DENTSPLY SIRONA Inc. reported a narrower net loss of $427 million in Q3 2025 compared to $494 million in Q3 2024, an improvement of 13.56%. However, total net sales declined by 5% to $904 million, driven by a significant 22.2% drop in U.S. sales, partially offset by a 10.09% increase in European sales. While cash reserves increased to $363 million, operating cash flow for the nine-month period saw a substantial decrease from $374 million to $134 million, indicating operational cash generation challenges.

Filing Stats: 5,216 words · 21 min read · ~17 pages · Grade level 18.9 · Accepted 2025-11-06 09:17:36

Filing Documents

Financial Statements (unaudited)

Financial Statements (unaudited) 4 Consolidated Statements of Operations 4 Consolidated Statements of Comprehensive Income (Loss) 5 Consolidated Balance Sheets 6 Consolidated Statements of Changes in Equity 7 Consolidated Statements of Cash Flows 9 Notes to Unaudited Interim Consolidated Financial Statements 9 Item 2

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 37 Item 3

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 51 Item 4

Controls and Procedures

Controls and Procedures 51 PART II OTHER INFORMATION Item 1

Legal Proceedings

Legal Proceedings 52 Item 1A

Risk Factors

Risk Factors 52 Item 2 Unregistered Sales of Securities and Use of Proceeds 54 Item 5 Other Information 54 Item 6 Exhibits 55

Signatures

Signatures 56 2 General Unless otherwise stated herein or the context otherwise indicates, references throughout this Form 10-Q to "Dentsply Sirona," or the "Company," "we," "us" or "our" refer to DENTSPLY SIRONA Inc., together with its subsidiaries on a consolidated basis.

Forward-Looking Statements and Associated Risks

Forward-Looking Statements and Associated Risks All statements in this Form 10-Q that do not directly and exclusively relate to historical facts constitute "forward-looking statements." These statements represent current expectations and beliefs, and no assurance can be given that the results described in such statements will be achieved. Such statements are subject to numerous assumptions, risks, uncertainties, and other factors that could cause actual results to differ materially from those described in such statements, many of which are outside of our control, including those described in Part I, Item 1A, "Risk Factors" of the Company's most recent Annual Report on Form 10-K, Part II, Item 1A, "Risk Factors" of the Company's Quarterly Reports on Form 10-Q for any subsequent fiscal quarters, and any updating information or other factors which may be described in the Company's other filings with the Securities and Exchange Commission (the "SEC"). No assurance can be given that any expectation, belief, goal or plan set forth in any forward-looking statement can or will be achieved, and readers are cautioned not to place undue reliance on such statements which speak only as of the date they are made. We do not undertake any obligation to update or release any revisions to any forward-looking statement or to report any events or circumstances after the date of this Form 10-Q or to reflect the occurrence of unanticipated events. Investors should understand it is not possible to predict or identify all such factors or risks. As such, you should not consider the risks identified in the Company's SEC filings to be a complete discussion of all potential risks or uncertainties associated with an investment in the Company. Disclosure Regarding Trademarks This report includes trademarks, trade names and service marks that are our property or the property of other third parties. Solely for convenience, such trademarks and trade names sometimes appear without any "" or

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

– Financial Statements

Item 1 – Financial Statements DENTSPLY SIRONA INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (in millions, except per share amounts) (unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Net sales $ 904 $ 951 $ 2,719 $ 2,888 Cost of products sold 463 456 1,322 1,376 Gross profit 441 495 1,397 1,512 Selling, general, and administrative expenses 355 390 1,055 1,204 Research and development expenses 37 40 110 123 Goodwill and intangible asset impairments 262 504 497 510 Restructuring and other costs 5 23 18 45 Operating loss ( 218 ) ( 462 ) ( 283 ) ( 370 ) Other income and expenses: Interest expense, net 23 18 66 53 Other income ( 11 ) ( 2 ) ( 10 ) ( 10 ) Loss before income taxes ( 230 ) ( 478 ) ( 339 ) ( 413 ) Provision for income taxes 198 17 114 69 Net loss ( 428 ) ( 495 ) ( 453 ) ( 482 ) Less: Net loss attributable to noncontrolling interest ( 1 ) ( 1 ) ( 1 ) ( 2 ) Net loss attributable to Dentsply Sirona $ ( 427 ) $ ( 494 ) $ ( 452 ) $ ( 480 ) Loss per common share attributable to Dentsply Sirona: Basic $ ( 2.14 ) $ ( 2.46 ) $ ( 2.27 ) $ ( 2.35 ) Diluted $ ( 2.14 ) $ ( 2.46 ) $ ( 2.27 ) $ ( 2.35 ) Weighted average common shares outstanding: Basic 199.5 201.0 199.3 204.7 Diluted 199.5 201.0 199.3 204.7 See accompanying Notes to Unaudited Interim Consolidated Financial Statements. 4 DENTSPLY SIRONA INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (in millions) (unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Net loss $ ( 428 ) $ ( 495 ) $ ( 453 ) $ ( 482 ) Other comprehensive (loss) income, net of tax: Foreign currency translation (loss) gain ( 8 ) 75 185 3 Net loss on derivative financial instruments ( 23 ) ( 36 ) ( 127 ) ( 5 ) Total other comprehensive (loss) income, net of tax ( 31 ) 39 58 ( 2 ) Total comprehensive loss ( 459 ) ( 456 ) ( 395 ) ( 484 ) Less: Comprehensive loss a

View on Read The Filing